BMY

Business Context and Reporting Period

Company: Bristol-Myers Squibb Company (BMS)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2008
Business Overview: BMS is a global biopharmaceutical company engaged in the discovery, development, and sale of pharmaceuticals and related health care products. The company operates through three reportable segments: Pharmaceuticals, Nutritionals (Mead Johnson), and ConvaTec.

Key Financial Metrics

*Free Cash Flow estimated as Operating Cash Flow less Capital Expenditures ($250M in Q1 2008, $202M in Q1 2007).

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 20% to $5.18 billion, driven by a 21% increase in Pharmaceuticals sales ($4.19 billion). Growth was fueled by strong performance in PLAVIX* (+39%), ABILIFY* (+24%), and BARACLUDE (+140%).
• Profitability: Earnings from continuing operations before taxes rose 51% to $1.29 billion. However, total net earnings declined 4% to $661 million due to a $43 million after-tax loss on the disposal of the Medical Imaging business.
• Restructuring: The company incurred $11 million in net restructuring charges in Q1 2008 as part of the Productivity Transformation Initiative (PTI), compared to $37 million in Q1 2007. Total PTI-related charges (including accelerated depreciation) were $113 million in Q1 2008.
• Tax Rate: The effective tax rate on continuing operations increased to 27.8% in 2008 from 8.0% in 2007. The 2007 rate was artificially low due to a $105 million tax benefit from the resolution of IRS matters and the expiration of the R&D tax credit.
• Investment Portfolio: The company recorded a $25 million impairment charge on Auction Rate Securities (ARS) and reclassified $104 million of Floating Rate Securities (FRS) to non-current assets due to market liquidity concerns.

Guidance, Outlook, and Risks

• Strategic Initiatives: BMS is executing the PTI, targeting $1.5 billion in annual cost savings by 2010. The company plans to sell approximately 10-20% of Mead Johnson Nutritionals via an IPO by the end of 2008.
• Product Pipeline: Expected to file a U.S. regulatory application for saxagliptin (diabetes) in mid-2008. New indications for ABILIFY* (pediatric bipolar) and ORENCIA (juvenile rheumatoid arthritis) were approved.
• Legal Risks (PLAVIX*): The company faces ongoing patent litigation regarding PLAVIX* in the U.S. (Apotex appeal pending), Canada (Supreme Court hearing held April 2008), and other jurisdictions. Loss of exclusivity would be material to sales and cash flows.
• Market Risks: Continued uncertainty in credit and capital markets poses a risk to the valuation of ARS and FRS holdings. The company believes current liquidity is sufficient to fund operations and dividends despite these market conditions.
• Dividends: The quarterly dividend was increased to $0.31 per share from $0.28.

Investor Verification Checklist

• PLAVIX* Patent Status: Verify the outcome of the Apotex appeal in the U.S. Federal Circuit and the Supreme Court of Canada decision, as these directly impact the $1.3 billion quarterly revenue stream.
• Investment Valuation: Monitor the fair value of the remaining $351 million in Auction Rate Securities and $204 million in Floating Rate Securities for further impairment charges.
• PTI Execution: Track progress on the $1.5 billion cost savings target and the associated one-time implementation costs.
• Discontinued Operations: Confirm the final net proceeds from the sale of the Medical Imaging business after working capital adjustments.
• Regulatory Filings: Watch for the submission of the saxagliptin NDA and the progress of the Mead Johnson Nutritionals IPO registration.